MedTrace Logo

The Spectralis-Cirrus Study

NCT00927303 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2010-06-09

No results posted yet for this study

Summary

Retinal thickness measurement is one of the most important examinations in the follow up of exudative age-related macular degeneration. Prior studies have shown that there are a series of algorithm line failures in OCT examinations. This study is conducted to compare the quality of the examinations of to different spectral domain OCT machines concerning the positioning of algorithm lines. Furthermore the reproducibility of the examinations id tested, both machines provide different techniques to guarantee that in repeated examinations the same location is examined.

Conditions

  • Exudative Age Related Macular Degeneration

Interventions

DEVICE

Cirrus-Spectralis

512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter

DEVICE

Spectralis-Cirrus

retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter

Sponsors & Collaborators

  • The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

    lead OTHER

Principal Investigators

  • Susanne Binder, MD, Prof · Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927303 on ClinicalTrials.gov